Clinical Trials
5 trialsNCT02275416 2024-12-16
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Ultimovacs ASA
Phase 1/2 Completed
NCT03538314 2024-08-22
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Ultimovacs ASA
Phase 1 Completed
NCT01875653 2019-05-10
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Lisata Therapeutics, Inc.
Phase 3 Terminated
NCT00769704 2016-07-13
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
BioVex Limited
Phase 3 Completed
NCT01368276 2015-12-18
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
BioVex Limited
Phase 3 Completed